Systematic Review of Escalated Imatinib Doses Compared with Sunitinib or Best Supportive Care, for the Treatment of People with Unresectable/Metastatic Gastrointestinal Stromal Tumours Whose Disease has Progressed on the Standard Imatinib Dose

INTRODUCTION: We conducted a systematic review of evidence on the effectiveness of imatinib at escalated doses of 600 mg/day or 800 mg/day for treatment of adults with unresectable or metastatic gastrointestinal stromal tumours (GIST), following progression on imatinib at the 400 mg/day dose, compar...

Descripción completa

Detalles Bibliográficos
Autores principales: Hislop, Jennifer, Mowatt, Graham, Sharma, Pawana, Fraser, Cynthia, Elders, Andrew, Jenkinson, David, Vale, Luke, Petty, Russell
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2011
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3348468/
https://www.ncbi.nlm.nih.gov/pubmed/21971958
http://dx.doi.org/10.1007/s12029-011-9325-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3348468/
https://www.ncbi.nlm.nih.gov/pubmed/21971958
http://dx.doi.org/10.1007/s12029-011-9325-6

Ejemplares similares